A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...

In the latest close session, Amgen (AMGN) was up +1.69% at $355.30. This move outpaced the S&P 500's daily gain of 1.2%. Elsewhere, the Dow gained 1.79%, while the tech-heavy Nasdaq added 1.52%. Prior ...

Amgen Inc. (NASDAQ:AMGN) is included among the 10 Healthcare Stocks with Highest Dividends. On April 13, UBS lifted its price ...

The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.

Amgen and Zai Lab have agreed to run a global clinical trial combining two DLL3 targeted therapies for small cell lung cancer ...

Amgen's Tepezza became the first drug approved by the FDA for thyroid eye disease (TED) in 2020, and the company is now looking to extend its role with a new, more patient-friendly formulation. The ...

Zai Lab (ZLAB) stock jumps as the company announces a global clinical trial collaboration with Amgen (AMGN). Read more here.

AmgenAMGN stock popped Wednesday on a solid third-quarter beat as investors focus on what's next for the company's obesity treatment, MariTide. Revenue from cholesterol treatment Repatha surged 40% to ...

Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.

Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide. The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, ...

The findings could help Amgen defend Tepezza’s market-leading position against emerging rivals, though some analysts ...

Evidence gaps include limited topline safety granularity, unknown long-term follow-up and retreatment rates, and lack of ...